5:10 PM
 | 
Jul 17, 2015
 |  BC Extra  |  Company News

QIDP for Motif's iclaprim triggers L22M placing

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif Bio plc (LSE:MTFB) to treat hospital-acquired bacterial pneumonia (HABP), triggering a L22 million ($34.1 million) placing. Motif sold 44 million shares at 50p to institutional investors including Aviva; Invesco; and Standard Life....

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >